Neumora Therapeutics Inc (NMRA) concluded trading on Thursday at a closing price of $2.16, with 4.47 million shares of worth about $9.66 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -81.91% during that period and on January 23, 2025 the price saw a gain of about 3.85%. Currently the company’s common shares owned by public are about 160.48M shares, out of which, 55.17M shares are available for trading.
Stock saw a price change of -1.82% in past 5 days and over the past one month there was a price change of -79.43%. Year-to-date (YTD), NMRA shares are showing a performance of -79.62% which decreased to -86.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.83 but also hit the highest price of $21.00 during that period. The average intraday trading volume for Neumora Therapeutics Inc shares is 2.82 million. The stock is currently trading -55.59% below its 20-day simple moving average (SMA20), while that difference is down -73.77% for SMA50 and it goes to -79.69% lower than SMA200.
Neumora Therapeutics Inc (NASDAQ: NMRA) currently have 160.48M outstanding shares and institutions hold larger chunk of about 29.80% of that.
The stock has a current market capitalization of $348.98M and its 3Y-monthly beta is at 2.16. It has posted earnings per share of -$1.85 in the same period. It has Quick Ratio of 10.98 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NMRA, volatility over the week remained 7.91% while standing at 10.58% over the month.
Analysts are in expectations that Neumora Therapeutics Inc (NMRA) stock would likely to be making an EPS of -0.37 in the current quarter, while forecast for next quarter EPS is -0.38 and it is -1.52 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.4 which is -0.28 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.71 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 55.97% while it is estimated to decrease by -0.72% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on January 02, 2025 offering a Sector perform rating for the stock and assigned a target price range of between $29 and $4 to it. Coverage by JP Morgan stated Neumora Therapeutics Inc (NMRA) stock as a Neutral in their note to investors on November 05, 2024, suggesting a price target of $15 for the stock. On October 01, 2024, H.C. Wainwright Initiated their recommendations, while on July 22, 2024, Needham Initiated their ratings for the stock with a price target of $23. Stock get an Outperform rating from Mizuho on July 08, 2024.
